Correcting a public health fiasco: The need for a new vaccine against lyme disease

Clinical Infectious Diseases

Volumn 52, Issue SUPPL. 3, 2011, Pages

  Plotkin, Stanley A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; LYME DISEASE VACCINE;

ADULT; ARTICLE; ARTIFICIAL HEART PACEMAKER; CASE REPORT; DRUG MARKETING; EMERGENCY WARD; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LYME DISEASE; MALE; PRIORITY JOURNAL; PUBLIC HEALTH; WESTERN BLOTTING; BORRELIA BURGDORFERI; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; IMMUNOLOGY; UNITED STATES;

BORRELIA BURGDORFERI; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HEALTH PRIORITIES; HUMANS; LYME DISEASE; LYME DISEASE VACCINES; PUBLIC HEALTH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79952543170     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq119     Document Type: Article

References (44)

1. Steere AC Lyme disease vaccines. In Plotkin SA, Orenstein WA, Offit PA eds. Vaccines. Philadelphia: Saunders-Elsevier, 2008; 1253-66.
2. Plotkin SA. Overview of vaccines. In: Khan OA, Readings in global health, a research anthology collected from the American Journal of Public Health. Washington, DC: APHA Press for American Public Health Association, 2005.
3. Nigrovic LE, Thompson KM. The Lyme vaccine: a cautionary tale. Epidemiol Infect 2007; 135:1-8. (Pubitemid 44811480)
4. Nadelman RB, Nowakowski J, Forseter G, et al. The clinical spectrum of early Lyme borreliosis in patients with cultureconfirmed erythema migrans. Am J Med 1996; 100:502-8.
5. Bacon RM, Kugeler KJ, Mead PS. Surveillance for lyme disease-United states, 1992-2006. MMWR Surveill Summ 2008; 57:1-9.
6. Anonymous. Lyme disease\Connecticut 2008. 29th ed. Connecticut Department of Public Health, 2009; 14-6.
7. Smith R, Takkinen J. Lyme borreliosis: Europewide coordinated surveillance and action needed? Euro Surveill 2006; 11:page E0606221.
8. Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of re-combinant borrelia burgdorferi outersurface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med 1998; 339:216-22. (Pubitemid 28350163)
9. Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outersurface lipopro-tein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 1998; 339:209-15. (Pubitemid 28350162)
10. CDC Recommendations for the use of Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1-5.
11. Vazquez M, Muehlenbein C, Cartter M, Hayes EB, Ertel S, Shapiro ED. Effectiveness of personal protective measures to prevent Lyme disease. Emerg Infect Dis 2008; 14:210-6. (Pubitemid 351213669)
12. Connally NP, Durante AJ, Yousey-Hindes KM, Meek JI, Nelson RS, Heimer R. Peridomestic Lyme disease prevention: results of a populationbased case-control study. Am J Prev Med 2009; 37:201-6.
13. Corapi KM, White MI, Phillips CB, Daltroy LH, Shadick NA, Liang MH. Strategies for primary and secondary prevention of Lyme disease. Nat Clin Pract Rheumatol 2007; 3:20-5.
14. Marwick C Guarded endorsement for Lyme disease vaccine. JAMA 1998; 279:1937-8. (Pubitemid 28298257)
15. Croke CL, Munson EL, Lovrich SD, et al. Occurrence of severe de-structive lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with Borrelia burgdorferi. Infect Immun 2000; 68:658-63. (Pubitemid 30056520)
16. Nardelli DT, Munson EL, Callister SM, Schell RF. Human Lyme disease vaccines: past and future concerns. Future Microbiol 2009; 4:457-69.
17. Drouin EE, Glickstein L, Kwok WW, Nepom GT, Steere AC Human homologues of a Borrelia T cell epitope associated with antibiotic-refractory Lyme arthritis. Mol Immunol 2008; 45:180-9. (Pubitemid 47331642)
18. Gross DM, Forsthuber T, Tary-Lehmann M, et al. Identification of LFA-1 as a candidate autoantigen in treatmentresistant Lyme arthritis. Science 1998; 281:703-6. (Pubitemid 28390407)
19. Kalish RA, Leong JM, Steere AC Association of treatmentresistant chronic Lyme arthritis with HLADR4 and antibody reactivity to OspA and OspB ofBorrelia burgdorferi. Infect Immun 1993; 61:2774-9. (Pubitemid 23182268)
20. Steere AC, Dwyer E, Winchester R. Association of chronic Lyme arthritis with HLADR4 and HLADR2 alleles. N Engl J Med 1990; 323:219-23. (Pubitemid 20225041)
21. Wallich R, Siebers A, Jahraus O, Brenner C, Stehle T, Simon MM. DNA vaccines expressing a fusion product ofouter surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease. Infect Immun 2001; 69:2130-6. (Pubitemid 32239678)
22. Ball R, Shadomy SV, Meyer A, et al. HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. Arthritis Rheum 2009; 60:1179-86.
23. Lathrop SL, Ball R, Haber P, et al. Adverse event reports following vaccination for Lyme disease: December 1998July2000. Vaccine 2002; 20:1603-8. (Pubitemid 34169801)
24. Rahn DW. Lyme vaccine: issues and controversies. Infect Dis Clin North Am 2001; 15:171-87. (Pubitemid 32268120)
25. McSweegan E. The Lyme vaccine: a cautionary tale. Epidemiol Infect 2007; 135:9-10.
26. Golde WT, Piesman J, Dolan MC, et al. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 1997; 65:882-9. (Pubitemid 27087986)
27. Van HC, Lebacq E, Beran J, Parenti D. Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine. Clin Infect Dis 1999; 28:1260-4. (Pubitemid 29272800)
28. Schoen RT, shefyLonghi T, Van-Hoecke C, Buscarino C, Fikrig E. An openlabel, nonrandomized, singlecenter, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicityofrecombinantoutersurface protein A (OspA) Lyme disease vaccine. Clin Ther 2003; 25:210-24. (Pubitemid 36206747)
29. Sikand VK, Halsey N, Krause PJ, et al. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial. Pediatrics 2001; 108:123-8. (Pubitemid 32592015)
30. Beran J, De CN, Dieussaert I, Van HC. Reactogenicity and immuno-genicity of a Lyme disease vaccine in children 2-5 years old. Clin Infect Dis 2000; 31:1504-7.
31. Feder HM Jr, Beran J, Van HC, et al. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme dis-ease in children. J Pediatrics 1999; 135:575-9.
32. Hsia EC, Chung JB, Schwartz JS, Albert DA. Costeffectiveness analysis of the Lyme disease vaccine. Arthritis Rheum 2002; 46:1651-60. (Pubitemid 34620214)
33. Shadick NA, Liang MH, Phillips CB, Fossel K, Kuntz KM. The cost-effectiveness of vaccination against Lyme disease. Arch Intern Med 2001; 161:554-61. (Pubitemid 32167520)
34. Meltzer MI, Dennis DT, Orloski KA. The cost effectiveness of vacci-nating against Lyme disease. Emerg Infect Dis 1999; 5:321-8. (Pubitemid 29289445)
35. Earnhart CG, Marconi RT. An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC typespecific se-quences. Hum Vaccin 2007; 3:281-9.
36. Koide S, Yang X, Huang X, Dunn JJ, Luft BJ. Structurebased de-sign of a secondgeneration Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. J Mol Biol 2005; 350:290-9. (Pubitemid 40805463)
37. Willett TA, Meyer AL, Brown EL, Huber BT. An effective second-generation outer surface protein Aderived Lyme vaccine that elimi-nates a potentially autoreactive T cell epitope. Proc Natl Acad Sci USA 2004; 101:1303-8. (Pubitemid 38182684)
38. Younus F, Luft BJ. Vaccines for Lyme disease. Curr Clin Top Infect Dis 2001; 21:349-65. (Pubitemid 33712820)
39. Brown EL, Kim JH, Reisenbichler ES, Hook M. Multicomponent Lyme vaccine: three is not a crowd. Vaccine 2005; 23:3687-96. (Pubitemid 40692414)
40. Pozsgay V, KublerKielb J. Synthesis of an experimental glycolipoprotein vaccine against Lyme disease. Carbohydr Res 2007; 342:621-6. (Pubitemid 46161417)
41. Edelman R, Palmer K, Russ KG, et al. Safety and immunogenicity of recombinant bacille CalmetteGuerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine 1999; 17: 904-14. (Pubitemid 29074745)
42. Hanson MS, Edelman R. Progress and controversy surrounding vaccines against Lyme disease. Expert Rev Vaccines 2003; 2: 683-703. (Pubitemid 37303898)
43. LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and antiOspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin Vaccine Immunol 2009; 16:253-9.
44. The Healthy People 2020. Improving the health of Americans. Available at: www.healthypeople.gov. Accessed 8 December 2010.